BSc MA - Cell Source Ex Chairman

All Insiders . USA . 
Stock . Cell Source . Stakeholders . Insider . BSc MA
CLCS Stock  USD 0.50  0.02  4.17%   

Insider

BSc MA is Ex Chairman of Cell Source
Age 73
Phone646 416 7896
Webhttps://www.cell-source.com

Cell Source Management Efficiency

The company has return on total asset (ROA) of (3.7761) % which means that it has lost $3.7761 on every $100 spent on assets. This is way below average. Cell Source's management efficiency ratios could be used to measure how well Cell Source manages its routine affairs as well as how well it operates its assets and liabilities.
Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ian LeitchOpthea
61
Behrad DerakhshanEdgewise Therapeutics
44
Alexander ZurcherMolecular Partners AG
49
Thomas SchwerzmannMolecular Partners AG
N/A
LLB JDAntibe Therapeutics
65
Alan RussellEdgewise Therapeutics
54
Ana StegicAntibe Therapeutics
N/A
MAICD MAICDOpthea
48
Matthew MBAIteos Therapeutics
51
James GodingOpthea
N/A
Annie LeeOpthea
N/A
Matthew GallIteos Therapeutics
47
Joanne MDIteos Therapeutics
52
CPA CPAOpthea
63
Yvonne McGrathIteos Therapeutics
50
Patrick AmstutzMolecular Partners AG
49
Philip SternAntibe Therapeutics
N/A
Christina BBAAntibe Therapeutics
N/A
Michael PitznerMolecular Partners AG
N/A
MBA MScAntibe Therapeutics
65
Ryan BakerIteos Therapeutics
N/A
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people. Cell Source [CLCS] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Asset-3.78

Cell Source Leadership Team

Elected by the shareholders, the Cell Source's board of directors comprises two types of representatives: Cell Source inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cell. The board's role is to monitor Cell Source's management team and ensure that shareholders' interests are well served. Cell Source's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cell Source's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itamar Shimrat, CEO and President CFO, Principal Accounting Officer and Director
BSc MA, Ex Chairman

Cell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cell Source a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-3.78
Current Valuation59.65 M
Shares Outstanding35.25 M
Shares Owned By Insiders32.13 %
Price To Earning(3.28) X
EBITDA(4.11 M)
Net Income(5.47 M)
Cash And Equivalents93.09 K
Total Debt6.5 M
Debt To Equity(1.04) %

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cell OTC Stock Analysis

When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY